Lista de obras -

Adalimumab therapy in children with Crohn disease previously treated with infliximab.

artículo científico publicado en 2015

Anti-Tumour Necrosis Factor Therapy for Paediatric Crohn's Disease: Improved Benefits Through Treatment Optimisation, Deeper Understanding of Its Risks, and Reduced Costs due to Biosimilar Availability.

artículo científico publicado en 2017

Benefits and risks of combining anti-tumor necrosis factor with immunomodulator therapy in pediatric inflammatory bowel disease

artículo científico

CMV Infection in Pediatric Severe Ulcerative Colitis - A Multicenter Study from the Pediatric IBD Porto Group of ESPGHAN.

artículo científico publicado en 2017

Cannabis, a potential treatment option in pediatric IBD? Still a long way to go

artículo científico publicado en 2019

Complications and Disease Recurrence After Primary Ileocecal Resection in Pediatric Crohn's Disease: A Multicenter Cohort Analysis

artículo científico publicado en 2017

Cytomegalovirus Infection in Pediatric Severe Ulcerative Colitis-A Multicenter Study from the Pediatric Inflammatory Bowel Disease Porto Group of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition

scientific article published in 2018

Development and Function of Immune Cells in an Adolescent Patient With a Deficiency in the Interleukin-10 Receptor

artículo científico publicado en 2017

Diagnostic and Therapeutic Approach in Paediatric Inflammatory Bowel Diseases: Results from a Clinical Practice Survey

artículo científico publicado en 2019

ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents

artículo científico

Endoscopy in Pediatric Inflammatory Bowel Disease: A Position Paper on Behalf of the Porto IBD Group of the Espghan

scientific article published on 02 August 2018

Endoscopy in Pediatric Inflammatory Bowel Disease: A Position Paper on Behalf of the Porto IBD Group of the European Society for Pediatric Gastroenterology, Hepatology and Nutrition

article by Salvatore Oliva et al published 1 September 2018 in Journal of Pediatric Gastroenterology and Nutrition

Eosinophilic myenteric ganglionitis as a cause of chronic intestinal pseudo-obstruction ⬇️

artículo científico publicado el 16 de diciembre de 2011

First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an open-label multicentre randomised controlled trial

artículo científico publicado en 2020

Infliximab Level Between Venous and Capillary Blood Using Novel Device Strongly Correlate in Paediatric IBD Patients

scientific article published on 14 August 2020

Infliximab More Effective in Therapy-Naïve Than in Therapy-Refractory Patients

artículo científico publicado en 2015

Infliximab therapy in 30 patients with refractory pediatric crohn disease with and without fistulas in The Netherlands

artículo científico publicado en 2004

International prospective observational study investigating the disease course and heterogeneity of paediatric-onset inflammatory bowel disease: the protocol of the PIBD-SETQuality inception cohort study

artículo científico publicado en 2020

Magnetic Resonance Enterography for Suspected Inflammatory Bowel Disease in a Pediatric Population ⬇️

artículo científico publicado el 1 de noviembre de 2010

Malignancy and mortality in paediatric-onset inflammatory bowel disease: a 3-year prospective, multinational study from the paediatric IBD Porto group of ESPGHAN.

artículo científico publicado en 2018

Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care- an Evidence-Based Guideline from ECCO and ESPGHAN

scientific article published on 30 May 2018

Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care-An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition

Management of Paediatric Ulcerative Colitis, Part 2: Acute Severe Colitis-An Evidence-based Consensus Guideline From the European Crohn's and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition

Management of Paediatric Ulcerative Colitis, Part 2: Acute Severe Colitis; An Evidence-based Consensus Guideline from ECCO and ESPGHAN

scientific article published on 30 May 2018

Manifestations of Munchausen syndrome by proxy in pediatric gastroenterology

artículo científico publicado en 2000

New Kids in the Neighborhood: Biosimilars

artículo científico publicado en 2017

Nutrition in Paediatric Inflammatory Bowel Disease: A Position Paper on Behalf of The Porto IBD Group of ESPGHAN.

artículo científico publicado en 2018

Nutrition in Pediatric Inflammatory Bowel Disease: A Position Paper on Behalf of the Porto Inflammatory Bowel Disease Group of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition

artículo científico publicado en 2018

Outcomes Following Pouch Formation in Paediatric Ulcerative Colitis: A Study from the Porto Group of ESPGHAN

artículo científico publicado en 2020

Paediatric multiple magnet ingestion

artículo científico publicado en 2021

Pharmacokinetics, Pharmacodynamics and Immunogenicity of Infliximab in Paediatric Inflammatory Bowel Disease; a Systematic Review and Revised Dosing Considerations

artículo científico publicado en 2020

Protocol for a multinational risk-stratified randomised controlled trial in paediatric Crohn's disease: methotrexate versus azathioprine or adalimumab for maintaining remission in patients at low or high risk for aggressive disease course

artículo científico publicado en 2020

The Continental Divide: Anti-TNF Use in Pediatric IBD Is Different in North America Compared to Other Parts of the World.

artículo científico publicado en 2018

The use of biosimilars in paediatric inflammatory bowel disease

artículo científico

Use of Biosimilars in Paediatric Inflammatory Bowel Disease: A Position Statement of the ESPGHAN Paediatric IBD Porto Group.

artículo científico publicado en 2015

Use of Biosimilars in Pediatric Inflammatory Bowel Disease: An Updated Position Statement of the Pediatric IBD Porto Group of ESPGHAN

artículo científico publicado en 2019

Use of Placebo in Pediatric Inflammatory Bowel Diseases: A Position Paper From ESPGHAN, ECCO, PIBDnet, and the Canadian Children IBD Network

artículo científico publicado en 2015

Vedolizumab Trough Levels in Children with Anti-TNF Refractory Inflammatory Bowel Disease

artículo científico publicado en 2020

Lista de obras de

Adalimumab therapy in children with Crohn disease previously treated with infliximab.

Anti-Tumour Necrosis Factor Therapy for Paediatric Crohn's Disease: Improved Benefits Through Treatment Optimisation, Deeper Understanding of Its Risks, and Reduced Costs due to Biosimilar Availability.

Benefits and risks of combining anti-tumor necrosis factor with immunomodulator therapy in pediatric inflammatory bowel disease

CMV Infection in Pediatric Severe Ulcerative Colitis - A Multicenter Study from the Pediatric IBD Porto Group of ESPGHAN.

Cannabis, a potential treatment option in pediatric IBD? Still a long way to go

Complications and Disease Recurrence After Primary Ileocecal Resection in Pediatric Crohn's Disease: A Multicenter Cohort Analysis

Cytomegalovirus Infection in Pediatric Severe Ulcerative Colitis-A Multicenter Study from the Pediatric Inflammatory Bowel Disease Porto Group of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition

Development and Function of Immune Cells in an Adolescent Patient With a Deficiency in the Interleukin-10 Receptor

Diagnostic and Therapeutic Approach in Paediatric Inflammatory Bowel Diseases: Results from a Clinical Practice Survey

ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents

Endoscopy in Pediatric Inflammatory Bowel Disease: A Position Paper on Behalf of the Porto IBD Group of the Espghan

Endoscopy in Pediatric Inflammatory Bowel Disease: A Position Paper on Behalf of the Porto IBD Group of the European Society for Pediatric Gastroenterology, Hepatology and Nutrition

Eosinophilic myenteric ganglionitis as a cause of chronic intestinal pseudo-obstruction ⬇️

First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an open-label multicentre randomised controlled trial

Infliximab Level Between Venous and Capillary Blood Using Novel Device Strongly Correlate in Paediatric IBD Patients

Infliximab More Effective in Therapy-Naïve Than in Therapy-Refractory Patients

Infliximab therapy in 30 patients with refractory pediatric crohn disease with and without fistulas in The Netherlands

International prospective observational study investigating the disease course and heterogeneity of paediatric-onset inflammatory bowel disease: the protocol of the PIBD-SETQuality inception cohort study

Magnetic Resonance Enterography for Suspected Inflammatory Bowel Disease in a Pediatric Population ⬇️

Malignancy and mortality in paediatric-onset inflammatory bowel disease: a 3-year prospective, multinational study from the paediatric IBD Porto group of ESPGHAN.

Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care- an Evidence-Based Guideline from ECCO and ESPGHAN

Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care-An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition

Management of Paediatric Ulcerative Colitis, Part 2: Acute Severe Colitis-An Evidence-based Consensus Guideline From the European Crohn's and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition

Management of Paediatric Ulcerative Colitis, Part 2: Acute Severe Colitis; An Evidence-based Consensus Guideline from ECCO and ESPGHAN

Manifestations of Munchausen syndrome by proxy in pediatric gastroenterology

New Kids in the Neighborhood: Biosimilars

Nutrition in Paediatric Inflammatory Bowel Disease: A Position Paper on Behalf of The Porto IBD Group of ESPGHAN.

Nutrition in Pediatric Inflammatory Bowel Disease: A Position Paper on Behalf of the Porto Inflammatory Bowel Disease Group of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition

Outcomes Following Pouch Formation in Paediatric Ulcerative Colitis: A Study from the Porto Group of ESPGHAN

Paediatric multiple magnet ingestion

Pharmacokinetics, Pharmacodynamics and Immunogenicity of Infliximab in Paediatric Inflammatory Bowel Disease; a Systematic Review and Revised Dosing Considerations

Protocol for a multinational risk-stratified randomised controlled trial in paediatric Crohn's disease: methotrexate versus azathioprine or adalimumab for maintaining remission in patients at low or high risk for aggressive disease course

The Continental Divide: Anti-TNF Use in Pediatric IBD Is Different in North America Compared to Other Parts of the World.

The use of biosimilars in paediatric inflammatory bowel disease

Use of Biosimilars in Paediatric Inflammatory Bowel Disease: A Position Statement of the ESPGHAN Paediatric IBD Porto Group.

Use of Biosimilars in Pediatric Inflammatory Bowel Disease: An Updated Position Statement of the Pediatric IBD Porto Group of ESPGHAN

Use of Placebo in Pediatric Inflammatory Bowel Diseases: A Position Paper From ESPGHAN, ECCO, PIBDnet, and the Canadian Children IBD Network

Vedolizumab Trough Levels in Children with Anti-TNF Refractory Inflammatory Bowel Disease